-
HanAll Biopharma Reports First Quarter 2021 Financial Results
prnasia
May 07, 2021
HanAll Biopharma announced on the 29th, Apr. that it achieved 27.8 billion won in sales, 5.4 billion won in operating profit and 4.5 billion won in net profit in the first quarter of this year.
-
Harbour BioMed, Chia Tai Tianqing Enter Biologics Partnership
contractpharma
May 16, 2019
Global collaboration focused on new antibody treatments in the fields of oncology and immunology.
-
Q BioMed, SRI Enter ASD Collaboration
contractpharma
December 17, 2018
Q Inc. has entered a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of
-
Huakang Biomed Holdings announces its share offering
biospectrumasia
December 03, 2018
The Group offers mainly three categories of IVD reagents, namely, male fertility IVD reagent, parasite antibody detection reagent and EBV antibody detection reagent
-
Q BioMed Announces FDA Filing for Strontium Chloride Sr89 Injection
americanpharmaceuticalreview
August 21, 2018
Q BioMed and BioNucleonics announce submission of a supplemental regulatory filing to the FDA for the approval of a new manufacturing facility. Once cleared by the FDA.....